Back to top
more

ABCELLERA BIOLG (ABCL)

(Delayed Data from NSDQ)

$4.36 USD

4.36
2,775,759

+0.02 (0.46%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $4.40 +0.04 (0.92%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?

by Zacks Equity Research

Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.

Zacks Equity Research

Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

by Zacks Equity Research

AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.

Zacks Equity Research

Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AbCellera Biologics (ABCL) stock based on the movements in the options market lately.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for AbCellera Biologics Inc. (ABCL) points to a 137.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AbCellera Biologics (ABCL) stock based on the movements in the options market lately.

Zacks Equity Research

Implied Volatility Surging for AbCellera (ABCL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roblox (RBLX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Roblox's (RBLX) first-quarter 2022 performance is expected to have benefited from growth in engagement hours and strength in the user base.

Zacks Equity Research

Ring Energy (REI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

A favorable commodity pricing scenario is likely to have aided Ring Energy's (REI) earnings in Q1.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

How Much Upside is Left in AbCellera Biologics Inc. (ABCL)? Wall Street Analysts Think 161%

by Zacks Equity Research

The consensus price target hints at a 160.5% upside potential for AbCellera Biologics Inc. (ABCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies

by Zacks Equity Research

AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.

Zacks Equity Research

Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen

by Zacks Equity Research

Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.